{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-5.439","upperLimit":"0.316","value":"-2.562"},{"groupId":"OG001","lowerLimit":"0.086","upperLimit":"4.842","value":"2.464"},{"groupId":"OG002","lowerLimit":"-1.722","upperLimit":"2.270","value":"0.274"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"31"}],"units":"Participants"}],"description":"Estimated using linear regression model, with baseline CD56\\^dim cells as the independent covariate, and maximal percent reduction in serum M protein as the dependent variable. For 1 patient who had nonmeasurable disease at baseline, the percent change in serum kappa-lambda difference was used instead of the percent change in serum M protein. Unit of measure=percent change from baseline in M protein cells/ percent change in CD56\\^dim cells (% chg from BL in M pro/% chg CD56\\^dim cs)","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants in 2 arms were enrolled sequentially. The first group of participants received elotuzumab intravenously at a dose of 20 mg/kg on Days 1 and 8 per 28-day cycle for Cycle 1 and then on Day 1 only in subsequent cycles.","id":"OG000","title":"Elotuzumab, 20 mg/kg"},{"description":"Participants in the second group received elotuzumab intravenously at a dose of 10 mg/kg weekly per 28-day cycle in Cycles 1 and 2, then on Days 1 and 15 in subsequent cycles.","id":"OG001","title":"Elotuzumab, 10 mg/kg"},{"description":"All participants on Elotuzumab therapy. Comprised of both the 20mg/kg and 10mg/kg arms","id":"OG002","title":"Elotuzumab, All Dosages"}],"paramType":"NUMBER","populationDescription":"All participants who received at least 1 dose of study drug and had the required data (4 participants did not have baseline data available).","reportingStatus":"POSTED","timeFrame":"From day of last patient, first dose to 6 months","title":"Linear Regression of Maximal Percent Reduction in Serum Monoclonal (M) Protein on Baseline Percent CD56^Dim Cells in Bone Marrow","type":"PRIMARY","unitOfMeasure":"% chg from BL in M pro/% chg CD56^dim cs"}